Cost-Effectiveness Analysis

Given the skyrocketing costs in today’s healthcare system, it is more important than ever to determine the most cost-effective treatments. Several CRHC faculty have expertise in conducting cost-effectiveness analysis across a variety of areas, including alcohol abuse, vaccination strategies, and costs of specific diseases and their complications. Faculty employ methods such as Markov simulation modeling, probabilistic sensitivity analysis, and value of information analysis in order to compare the cost-effectiveness of different interventions and strategies and the impact of different screening methods on clinical outcomes and costs. Such analyses, which enable estimations of incremental cost per quality-adjusted life-year gained for the comparative interventions, ultimately allow clinicians to determine the optimal strategies to be incorporated into clinical practice and enable researchers to identify the most valuable areas for future research.


Kevin L. Kraemer, MD, MSc

Dr. Kraemer’s research interests are in the delivery and implementation of patient-centered strategies for the detection and early intervention of unhealthy alcohol and drug use, the application of cost-effectiveness methodology to alcohol and drug detection and treatment programs, and the comparative effectiveness of alcohol and drug addiction treatment on HIV outcomes and quality of HIV care. 

Kenneth J. Smith, MD, MS

Dr. Smith’s research centers on the cost-effectiveness of common medical interventions, most notably on pneumococcal, influenza, and varicella vaccination, and on the impact of racial disparities in vaccination rates. He has published in many other areas, including pelvic inflammatory disease, influenza management strategies, diabetes prevention and treatment, VA formulary decisions, anticoagulation and thrombotic disorder management, and hospital-physician communication.